| [1] |
|
| [2] |
Lasrado N, Reddy J．An overview of the immune mechanisms of viral myocarditis[J]． Rev Med Virol， 2020， 30(6):1-14.DOI： 10.1002/rmv.2131.
|
| [3] |
Kitaoka H, Tsutsui H, Kubo T，et al.JCS/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies[J]． Circ J， 2021， 85(9):1590-1689.DOI： 10.1253/circj.CJ-20-0910.
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Bozkurt B, Colvin M, Cook J，et al.Current diagnostic and treatment strategies for specific dilated cardiomyopathies：a scientific statement from the American heart association[J]． Circulation， 2016， 134(23):e579-e646.DOI： 10.1161/CIR.0000000000000455.
|
| [9] |
中华心血管病杂志编辑委员会心肌炎心肌病对策专题组，杨英珍．关于成人急性病毒性心肌炎诊断参考标准和采纳世界卫生组织及国际心脏病学会联合会工作组关于心肌病定义和分类的意见[J]．中华心血管病杂志，1999，27(6):405-407.
|
| [10] |
Miller DT, Lee K, Gordon AS，et al.Recommendations for reporting of secondary findings in clinical exome and genome sequencing，2021 update：a policy statement of the American College of Medical Genetics and Genomics (ACMG)[J]． Genet Med， 2021， 23(8):1391-1398.DOI： 10.1038/s41436-021-01171-4。
|
| [11] |
Orphanou N, Papatheodorou E, Anastasakis A．Dilated cardiomyopathy in the era of precision medicine：latest concepts and developments[J]． Heart Fail Rev， 2022， 27(4):1173-1191.DOI： 10.1007/s10741-021-10139-0.
|
| [12] |
Carnevale A, Rosas-Madrigal S, Rosendo-Gutiérrez R，et al.Genomic study of dilated cardiomyopathy in a group of Mexican patients using site-directed next generation sequencing[J]． Mol Genet Genomic Med， 2020， 8(11):e1504.DOI： 10.1002/mgg3.1504.
|
| [13] |
Nguyen TV, Tran Vu MT, Do T，et al.Genetic determinants and genotype-phenotype correlations in Vietnamese patients with dilated cardiomyopathy[J]． Circ J， 2021， 85(9):1469-1478.DOI： 10.1253/circj.CJ-21-0077.
|
| [14] |
McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms[J]． Circ Res， 2017， 121(7):731-748.DOI： 10.1161/CIRCRESAHA.116.309396.
|
| [15] |
|
| [16] |
Mazzarotto F, Tayal U, Buchan RJ，et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy[J]． Circulation， 2020， 141(5):387-398.DOI： 10.1161/CIRCULATIONAHA.119.037661.
|
| [17] |
Zegkos T, Panagiotidis T, Parcharidou D，et al.Emerging concepts in arrhythmogenic dilated cardiomyopathy[J]． Heart Fail Rev， 2021， 26(5):1219-1229.DOI： 10.1007/s10741-020-09933-z.
|
| [18] |
Pugh TJ, Kelly MA, Gowrisankar S，et al.The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing[J]． Genet Med， 2014， 16(8):601-608.DOI： 10.1038/gim.2013.204.
|
| [19] |
Yuan ZY, Cheng LT, Wang ZF，et al.Desmoplakin and clinical manifestations of desmoplakin cardiomyopathy[J]． Chin Med J (Engl)， 2021， 134(15):1771-1779.DOI： 10.1097/CM9.0000000000001581.
|
| [20] |
Heliö K, Kangas-Kontio T, Weckström S, et al. DSP p．(Thr2104Glnfs*12) variant presents variably with early onset severe arrhythmias and left ventricular cardiomyopathy[J]． BMC Med Genet， 2020， 21(1):19.DOI： 10.1186/s12881-020-0955-z.
|
| [21] |
Merlo M, Masè M, Vitrella G, et al. Usefulness of addition of magnetic resonance imaging to echocardiographic imaging to predict left ventricular reverse remodeling in patients with nonischemic cardiomyopathy[J]． Am J Cardiol， 2018， 122(3):490-497.DOI： 10.1016/j.amjcard.2018.04.017.
|
| [22] |
Cojan-Minzat BO, Zlibut A, Agoston-Coldea L．Non-ischemic dilated cardiomyopathy and cardiac fibrosis[J]. Heart Fail Rev, 2021, 26(5):1081-1101. DOI： 10.1007/s10741-020-09940-0.
|
| [23] |
|
| [24] |
Fatkin D, Huttner IG, Kovacic JC，et al.Precision medicine in the management of dilated cardiomyopathy：JACC State-of-the-Art Review[J]． J Am Coll Cardiol， 2019， 74(23):2921-2938.DOI： 10.1016/j.jacc.2019.10.011.
|
| [25] |
Morales A, Kinnamon DD, Jordan E，et al.Variant interpretation for dilated cardiomyopathy：refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study[J]． Circ Genom Precis Med， 2020， 13(2):e002480.DOI： 10.1161/CIRCGEN.119.002480.
|